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Abstract 
A new method to track cells in vivo utilizes proton (1H) magnetic resonance imaging 
(MRI) with 19fluorine MRI. Cells can be labeled ex vivo with the 19F reagent prior to 
transplantation and imaged with MRI to generate a signal detected by a custom made, dual-tone 
fluorine coil to show transplanted cell “hotspots” in the host tissue. Oligodendrocyte Progenitor 
Cells (OPCs) are an ideal cell population for cellular therapy in traumatic spinal cord injury due 
to their ability to remyelinate and support axons after injury. OPCs can be labeled with 19F at a 
similar efficiency as other cell types, confirmed by fluorescence microscopy and NMR 
spectroscopy. Potential real-time, in vivo cellular tracking of transplanted OPCs would allow for 
analysis of cell migration after transplantation, comparison of functional analysis with 
transplanted cell numbers and location at multiple time points for each animal, and quantification 
of transplanted cells. Cell characterization of transplanted iPSC derived OPCs in injured rat spinal 
cords has been optimized, and can be translated to 19F labeled cell transplants in the future. The 
FDA approved Cell Sense 19F reagent allows for direct translation to use in humans for cell 
visualization and tracking that is not possible in current clinical trials for cellular therapies. 
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Introduction 
Oligodendrocyte Progenitor Cells  
 Oligodendrocyte Progenitor Cells (OPCs) and oligodendrocytes are an important cell 
lineage because of their myelinating function in the central nervous system (CNS) and therapeutic 
potential. The tightly compacted myelin sheath produced by oligodendrocytes is composed of 
lipid rich membranes wrapped around axons. This creates regions of high resistance and low 
capacitance, essential for efficient neuronal electrical signal conductance 1. The distribution of 
voltage gated ion channels in the axons are organized by the myelin internodes to generate 
efficient signal conduction throughout the neuroaxis 2. The myelin sheath also provides support to 
the axons and plays a critical role in maintaining axon integrity through protection during 
inflammatory events. 
 During embryogenesis in vertebrates, three distinct progenitor cell populations give rise 
to functionally redundant neuroepithelial precursor cells called OPCs that form all of the 
oligodendrocytes in the adult brain 3,4. The majority (90%) of OPCs that populate the spinal cord 
are generated in the pMN domain of the ventral ventricular zone, and the remaining 10% are 
generated in a dorsal region of the spinal cord later in development. Olig2 positive cells in the 
pMN domain give rise to motor neurons and OPCs, following a neuronal/gliogenic switch, and a 
small subset of these cells give rise to astrocytes and ependymal cells 4–6. Although most OPCs 
differentiate into mature oligodendrocytes, some OPCs persist into adulthood and aid in 
oligodendrocyte turnover and potentially myelin repair after minor injury in the CNS 7. However, 
this is insufficient to provide sufficient functional recovery after spinal cord injury.       
In response to injury and demyelination, endogenous OPCs are activated, primarily 
through inflammatory mediators, and begin the process of remyelination. The activated OPCs 
migrate to the area of damage through chemotaxis and proliferate8. At the site of damage, the 
OPCs begin to differentiate into oligodendrocytes and produce myelin to insulate the exposed 
  2 
axons. Exposed axons are subject to irreversible damage and degradation. This dynamic process 
emphasizes the importance of OPCs in the adult CNS to act as a stem cell population, 
maintaining the levels of OPCs and mature oligodendrocytes (see Figure 1)1,9. This is necessary 
because the non-migratory and post-mitotic nature of mature oligodendrocytes prevents them in 
aiding the remyelination process 8.  
 
Figure 1: Myelination in the Central Nervous System 
Figure 1: Myelination in the Central Nervous System. Figure adapted from Crawford et al. 2013. Under 
normal physiologic conditions, oligodendrocytes have produced the protective myelin sheath enveloping 
axons (a). After trauma due to injury or disease, oligodendrocyte death and demyelination of axons occurs 
(B). In response, OPCs in the adult tissue are activated and migrate to the area of demyelination through 
chemotaxis (C). Once in the proper location, OPCs begin to differentiate into oligodendrocytes and 
remyelinate the exposed axons.  
 
Many groups are working to derive OPCs from rodent and human embryonic stem (ES) 
cells 10–15 and induced pluripotent stem (iPS) cells 16–18. However, in most cases the derivation of 
OPCs vary in quantity and quality resulting from inconsistencies between protocols, and the 
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reproducibility of results needs to be established (reviewed in 9). Additionally, these protocols are 
ultimately not clinically relevant as they are not translatable to Good Manufacturing Practice, a 
requirement for clinical use. 
  
Oligodendrocyte Progenitor Cells and Spinal Cord Injury 
The use of OPCs in the treatment of demyelinating diseases, including leukodystrophies, 
multiple sclerosis (MS), and spinal cord injury (SCI), has been proposed, both through activation 
of endogenous OPCs and transplantation of exogenous, cultured OPCs.  
After traumatic SCI, there is immediate death of neurons, oligodendrocytes, astrocytes, 
and endothelial cells at the injury location, known as the primary injury. Death of endothelial 
cells results in hemorrhage, leading to vascular damage and inflammation. This is followed by 
spreading of secondary injury due to cell necrosis, which is worsened by macrophage and 
lymphocyte infiltration. Cell death and tissue loss during this phase can be attributed to ischemia, 
excitotoxicity of the microenvironment, edema, and inflammation. This ultimately leads to spinal 
cord atrophy with the presence of fluid filled cysts during the chronic phase after injury (reviewed 
in 19).  
A major effect of SCI is the death of oligodendrocytes at the site of injury and in distant 
areas from the impact site. This is thought to contribute to the loss of function following SCI. 
Apoptosis of distant oligodendrocytes is likely a result of an autoimmune reaction of MBP-
reactive T cells infiltrating the spinal cord after injury 20. This is supported by evidence that 
suppression of the adaptive immune response provides neuroprotection after SCI.  
Following traumatic SCI, there is evidence for endogenous stem and progenitor 
population activation. Cell division and proliferation of these populations is seen as early as 24 
hrs after injury. These populations give rise to new glial cells and the generation of new myelin in 
the injured cord 21. However, the spontaneous remyelination seen after injury generally produces 
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thin myelin that is unable to compensate for the degraded myelin sheath. These findings of 
endogenous progenitor cell activation in the CNS indicate potential roles for these cells in 
therapies following SCI and CNS damage.  
   Due to the lack of self-regeneration and definitive treatment options following 
traumatic SCI, cell replacement therapies are a viable option to help restore function after 
traumatic SCI. In particular, the transplantation of OPCs holds great potential due to their ability 
to migrate and remyelinate axons at the site of injury. Several groups have investigated the use of 
OPCs derived from pluripotent stem cells to increase functional recovery, and have seen 
promising results in animal models 11,13,22–24. Additionally, a phase 1 clinical trial was previously 
approved to test the safety of human embryonic stem cell (hESC) derived OPCs in patients with 
subacute SCI 25.   
 
Cell Tracking in Transplantation Studies 
In cell transplantation studies, the most common method of identifying transplanted cells 
is through post mortem analysis via immunohistochemistry (IHC). This can be done through 
particular staining of antigens specific to donor cells or lineage tracing of donor cells. For 
example, donor cells can be derived from an animal containing an eGFP reporter, such as the 
mouse OPCs utilized in this thesis, which can be detected in the host tissue, using fluorescence 
microscopy. If the donor and host cells are of different species, there are also species specific 
antigens, such as human Nuclear Antigen and the human cytoplasmic marker SC121 26, to detect 
transplanted cells in the host tissue.  
Although these methods of immunohistochemistry work well, there are many 
disadvantages to this form of cell tracking. For instance, the post mortem analysis limits each 
tissue sample to only one time point for analysis. This can present challenges for transplantation 
studies, especially those investigating migratory cells. If there is no initial marking of the 
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transplantation site, it can be challenging to accurately measure migration patterns and distances 
traveled in vivo. This type of analysis requires many animal subjects in the studies to allow for a 
sufficient amount of data to be collected at each time point to accurately describe cell 
characteristics and location over a timeline.  
To account for these shortcomings, many researchers are developing methods of tracking 
cells in vivo using magnetic resonance imaging (MRI) and other imaging techniques commonly 
used in humans. MR imaging has advantages over other methods as it provides high-resolution 
images without exposing patients to potentially harmful radiation that occurs with other imaging 
techniques, such as Computed Tomography (CT), Positron Emission Tomography (PET), and x-
ray imaging. This is especially important for patients participating in a treatment that would 
require regular scans, such as tracking transplanted cells.  
 
In Vivo Cell Tracking with 19F 
One particular imaging technique that is gaining popularity utilizes an isotope of fluorine, 
19F 27. This is a non-radioactive element that is stable in nature. 19F NMR spectroscopy has been 
used since the 1970’s to study proteins and biological materials 28. This technology has recently 
expanded to utilize 19F for imaging through the use of perfluorocarbon (PFC) - based cell labels. 
PFCs are the most biologically inert organic molecules produced and are non-toxic to cells, even 
at high doses 29. Fluorocarbons do not degrade at lysosomal pH values and there are no known 
enzymes that metabolize the compounds, likely due to the strong, covalent C-F bond 30. 19F has 
many characteristics that make it ideal for MR imaging, including its non-toxic and stable nature, 
and its infrequency in biological materials creating low background 29. MR imaging is 
accomplished utilizing the natural magnetic properties of organisms. Typically, the hydrogen 
nucleus is used to generate an image because of its abundance in the body. Using the strong 
magnetic field of the MRI scanner, the protons align uniformly in the magnetic field. By 
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changing the local magnetic field through a series of gradient electric coils, different tissues of the 
body will produce different signal intensities. Additional wave pluses at radio wave frequency 
cause the hydrogen nuclei to resonate and emit a signal once the radiofrequency is shut off. This 
signal is received and plotted to generate stacked, cross sectional images 31. 
Another method utilized by labs to track cells in vivo with MRI is cell labeling with 
superparamagnetic iron oxide nanoparticles (SPIOs). SPIOs are clinically used T2 contrast agents. 
These SPIOs were not designed to be intracellular labels and can only be taken up by phagocytes 
or the use of transfection agents is required for intracellular labeling. Recently, SPIOs have been 
coated with dextran or heparin (HSPIO), which allows them to enter non-phagocytic cells32. This 
labeling approach has been used by multiple groups to track transplanted stem cells in vivo in 
mouse and rat models, including studies focused on the CNS33. These studies have emphasized 
the possibility and importance of tracking transplanted cells using conditions that are clinically 
relevant. However, the SPIOs often look like blood on the MR image. Areas of hemorrhage make 
it difficult to distinguish the iron-oxide containing stem cells, providing a large obstacle in cell 
tracking33.        
In comparison to more commonly used metal ion- based contrasts that rely on 1H-MRI 
imaging, 19F imaging utilizes  multi-nuclear MRI that will not interfere with T2- or diffusion-
weighted imaging 34. To accomplish this, a different radiofrequency is used to detect fluorine 
nuclei and generate an image of fluorine signals overlaid with the corresponding 1H image. For 
example, a study conducted by Bible et al. utilized this technique to track 19F labeled human 
neural stem cells transplanted into a stroke model. With this reagent they were able to perform 
real-time imaging to confirm that the transplanted cells were injected into the correct area of the 
brain and did not migrate out of this area after transplantation.  
Another important factor in measuring recovery after stroke injury is to observe the 
lesion cavity size, imaged by diffusion MRI. Diffusion MRI is a type of 1H imaging that can be 
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affected with the use of metal oxide labeling, such as iron oxide or gadolinium, decreasing the 
ability to analyze stroke pathology with MRI. With the use of 19F labeling agent, this group was 
able to visualize the transplanted human neural stem cells and make accurate measurements of the 
lesion cavity using multi-nuclear MRI.  
19F cell imaging has great implications in the field of cellular therapy. One large obstacle 
to FDA approval of cell therapies is the inability to track the persistence and location of 
transplanted cells. This technology is safe for human use and provides a platform to measure cell 
quantity and location in vivo while simultaneously tracking functional improvement 35–37. 
Multiple types of PFC have been developed, however the ideal compound for imaging 
contains a simple NMR spectrum with a single peak. NMR spectroscopy measures the amount of 
fluorine nucleus spins in a strong magnetic field after exposure to an appropriate radiofrequency. 
19F NMR spectroscopy is a useful tool in quantifying 19F. Magnetically nonequivalent fluorine 
molecules will generate multiple peaks on the spectrum. A single peak, representing magnetically 
equivalent fluorine molecules, is ideal to generate a maximized signal intensity for the PFC. The 
particular FDA approved nanoemulsion 19F compound, Cell Sense, generated by the company 
Celsense, is a linear perfluoropolyether (PFPE) polymer. This PFPE is an ideal 19F compound 
because of its single NMR resonance peak and small T1/T2 ratio, providing an intense signal with 
minimal background with MRI. The linear structure of this compound allows it to be conjugated 
to other compounds, such as fluorescent dyes, for increased functionality 29. This also gives the 
PFPE self-delivering abilities that allow the compound to enter the cell without the need for 
transfection, making the compound easy and safe to use 38. This is in contrast to the metal ion 
labeling techniques that may require transfection to label non-phagocytic cells.         
 Cell Sense has been used to label a variety of different cell types, including T cells, 
dendritic cells, hematopoietic stem cells, neural stem cells, and mesenchymal stem cells 37,39–41. A 
phase I clinical trial is currently ongoing using Cell Sense to label therapeutic cells ex vivo. The 
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study is investigating an immunotherapeutic dendritic cell vaccine to treat stage-4 colorectal 
cancer 35. The goal of the study is to show the safety of both the dendritic cell vaccine and the 
Cell Sense reagent. The vaccine was injected into peripheral tissue, with the intention that the 
cells would migrate to the lymph node. In the three participating patients, there is a decreased 
signal in the area of injection 24 hrs following transplantation, indicating that roughly half of the 
injected cells were no longer at the site of injection and had potentially migrated to the lymph 
node or other tissues.  
The versatility of PFCs is emphasized in this clinical trial and previous studies. 19F is an 
easy to use cell label to visualize either transplanted cells that migrate after transplantation in a 
short term imaging study, or for prolonged imaging of transplanted cells that remain stationary 
after injection, as in the models of stroke 42,43. The intensity of the signal produced by the 19F can 
be used to quantify the number of labeled cells, which is important for transplantation studies but 
can prove to be challenging using conventional IHC methods. This is especially true in human 
clinical trials, where quantification of transplanted cells is important for evaluation of safety and 
efficacy but is currently challenging. Additionally, the short term imaging approach can confirm 
proper transplantation, both in cell number and location, relatively soon after the procedure. This 
is especially useful for difficult procedures that often result in graft failures, such as cell therapies 
for spinal cord injury 26. Without in vivo imaging, it is impossible to know if the therapeutic cells 
were properly delivered until the tissue is harvested and processed post mortem. This is 
problematic for evaluating efficacy of cell therapies in clinical trials and can result in an increased 
number of animals used in pre-clinical studies as well as increased costs and duration of the 
study.       
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In Vivo Cell Tracking of Transplanted Oligodendrocyte Progenitor Cells 
Despite the range of cell types that have been studied with PFC tracking, no studies have 
been conducted in spinal cords or with OPCs. The studies done on human neural stem cells 
indicates that cells in the CNS can be labeled and imaged using these techniques. However, most 
of the studies that have been conducted are on either highly migratory cells, for example dendritic 
cells and T lymphocytes, or stationary cells, such as neural stem cells in a scaffold 34,36,40. OPCs 
are an intermediate to those cell types; OPCs are able to migrate through the spinal cord to the 
site of injury, however this is a smaller environment than the hematopoietic or lymphatic systems. 
Thus, it is possible that the migration of OPCs could be visualized at early time points after 
transplantation, in addition to observing their long term location in the spinal cord. Using 19F 
tracking would allow for the confirmation that transplanted OPCs can migrate to the injury site, 
while observing any pathological improvements in the spinal cord with MRI. Of the ongoing 
clinical trials using cellular therapies to treat SCI, it is difficult to precisely determine if the 
functional improvements are a result of the transplanted cells or if they are a result of another 
phenomenon. in vivo tracking would shed light on these important questions. 
 The purpose of this study is to validate the safety and non-toxicity of 19F Cell Sense 
reagent in iPS cell derived OPCs and to determine if this is a viable method of in vivo cell 
tracking of transplanted OPCs in injured rat spinal cords (Part A). ex vivo labeling analysis is 
confirmed with NMR spectroscopy and viability testing. Effectiveness of in vivo tracking will be 
confirmed with normal histological, post mortem analysis. Therefore it is important to optimize 
cell tracking and characterization using immunohistochemistry in OPC transplantation 
experiments without the 19F Cell Sense reagent (Part B). If in vivo tracking of iPS cell derived 
OPCs is possible in the injured rat spinal cord, this would provide more insight to the role of 
transplanted OPCs in injured cords. This potential application is directly translatable to human 
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use in the current and future clinical trials transplanting OPCs in injured spinal cords given the 
safety and FDA approval of the 19F Cell Sense reagent.  
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Materials and Methods 
Part A: Cell Labeling and Tracking with 19Fluorine 
Mouse Oligodendrocyte Progenitor Cells 
 Mouse iPS cell derived OPCs have been previously generated in the Parr lab from 
Oct4:CreER mGmT iPS cells 44. These cells express transmembrane eGFP. The cell population 
was profiled using immunocytochemistry and quantitative PCR (qRT-PCR), confirming a 
heterogeneous population containing a majority of OPCs and small percentage of neural and 
astroglial markers.  
 
Mouse Cell Culture 
Frozen mOPCs were provided in culture or thawed at room temperature. After removing the 
cells, the Cryovial® was washed two times with mOPC media, containing the base media 
Dulbecco’s Modified Eagle Medium/ Nutrient Mixture F-12 (DMEM/F-12) (Gibco® by Life 
Technologies), 2% B27 Supplement (Gibco® by Life Technologies), 1% N2 Supplement 
(Gibco® by Life Technologies), 1% Penicillin/Streptomycin (Corning Cellgro), 0.001% 
Recombinant Human Sonic Hedgehog (Shh) (C24II) N-Terminus (100 µg/mL) (R and D 
Systems), 0.0002% Recombinant Human FGF (146 aa) Basic (100µg/mL) (R and D Systems), 
and 0.0002% PDGF-AA Human (100 µg/mL) (Sigma-Aldrich). This mOPC media was 
optimized for the appropriate combination and balance of growth factors previously by the Parr 
lab. After cell removal and washing, the freezing media, 10% DMSO in mOPC media, was 
diluted 1 to 10 with growth media in a 15 mL conical and the suspension was centrifuged at 1000 
RPM for 5 minutes. The supernatant was removed, and the pellet was resuspended in 1 mL of 
mOPC media using a p1000 pipettor. An additional 5 mL of mOPC media was added to the cells, 
and 1 mL of the cellular solution was added to each well of a prepared 6 well plate. The 6 well 
pate was prepared by coating each well with 1 mL poly-ornithine 50 µg/mL (Sigma-Aldrich) for 
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1 hr, up to 24 hours. The poly-ornithine was removed, and each well was washed twice with 1 
mL of sterile water and then with 1 mL of Fibronectin (50 µg/mL) (Sigma-Aldrich). Finally, each 
well received 1 mL of mOPC media before adding the cellular suspension. The cells were evenly 
distributed throughout the plate and incubated at 37° C, 5% CO2. The following day the media 
was changed, followed by subsequent media changes every 2 days while the cells were 
maintained in culture. When cells became 90% confluent, typically after 3 days in culture, the 
cells were passed. 
During passaging, the media was removed from the wells. Each well was washed with 1 
mL sterile PBS and 1 mL of accutase (Millipore) was added to each well to enzymatically detach 
the cells from the plate. The cells were incubated with accutase for 5-10 minutes at room 
temperature, until the cells were round and detached from the plate on their own. The cell 
suspension was collected in an appropriate conical, most commonly three 15 mL conicals, with 2 
wells per conical. Each well was rinsed twice with 1 mL mOPC media each, adding the solution 
to the respective conical. The conicals were then filled with media to properly dilute the accutase 
and prevent cell damage or death and the cells were pelleted. The supernatant was aspirated and 
each cell pellet was resuspended in 1 mL of mOPC media. An additional 5 mL of mOPC media 
was added, and each conical was evenly distributed to one previously prepared 6 well plate for a 
1 to 3 passage. The media was changed on the following day, with media changes occurring 
every other day after.  
 
Human Cell Culture 
 Human Lung Fibroblasts (HLF) were used in early experiments to test labeling 
efficiencies and viability after 19F labeling. The cells were provided in live culture and were 
maintained in HLF media provided. 
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 Human iPSC derived OPCs (hOPCs) were provided in live culture for 19F labeling to 
ensure safe uptake the 19F reagent. hOPCs were maintained on Laminin (20 µg/mL, Life 
Technologies) coated plates in provided hOPC medium, N2/B27 Basal media supplemented with 
triiodothyronine (40 ng/mL), Insulin-like Growth Factor-1, Neurotropin-3, Platelet-Derived 
Growth Factor AA (20 ng/mL), and Epidermal Growth Factor.  
In all cell cultures, the cells were routinely monitored for signs of contamination. 
 
Cell Viability  
 Cell viability was measured based on morphology and Trypan Blue staining. Cell 
morphology was routinely observed using microscopy. During cell passaging or harvesting, a 
small aliquot was removed for quantification and viability testing by diluting the aliquot with 
Trypan Blue. The cells were counted using a hemocytometer and the total cell counts and percent 
of blue, or dead cells, was recorded.     
 
Labeling Human Lung Fibroblasts and Oligodendrocyte Progenitor Cells with 19F  
The cell labeling experiments were done to determine the optimal loading of fluorine in 
HLFs and OPCs with the greatest cell survival and intracellular 19F concentration. 
The company Celsense generated a perfluorocarbon (PFC) cell labeling product 
optimized for ex vivo cell labeling for transplantation studies called Cell Sense (CS-ATM). This 
is a linear perfluoropolyether (PFPE) polymer containing >20 19F molecules 38. The linear nature 
of this compound allows it to be directly conjugated to a fluorescent dye, here the red BODIPy-
TR dye was used. The linear PFPE is formulated into a nanoemulsion with an FDA approved 
copolymer, F68, and a polyamine containing both primary and secondary amine groups, essential 
for cellular uptake 38. This nanoemulsion compound is called CS-ATM DM Red, hereafter 
referred to as CS-ATM.   
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In initial experiments, HLF cells were used to determine labelling protocols and toxicity 
of CS-ATM. HLF cells were provided live in culture were incubated in CS-ATM for 24 hrs. Ten 
different concentrations of CS-ATM were used, 2.5, 5, 7, 10, 12.5, 15, 17, 20, 25, and 30 mg/mL, 
diluted with HLF media. Two negative controls with only HLF media were included. After the 24 
hr incubation period, the cells were washed several times with sterile phosphate buffered solution 
(PBS) and kept in culture for two additional days. At the end of this time the cells were analyzed 
for fluorine uptake and viability.  
Figure 2: The CS-ATM DM Red 19F Compound. Figure adapted from Janjic et al. The PFPE polymer 
with 19F molecules is conjugated to a fluorescent dye (BODIPy-TR) for dual functionality, with the end 
result designated as FBPA here (A). The FBPA undergoes microfluidization with F68, a compound 
with hydrophobic polypropylenoxie (PPO) and hydrophilic polyethylene oxide (PEO) groups, and a 
polyamine to generate the nanoemulsion used for cell labeling.  
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Similar labeling experiments were repeated with mOPCs. The cells were incubated in 
culture for 24 hrs with CS-ATM. CS-ATM was diluted in mOPC media to achieve the 
concentrations of 2.5, 3, 5, 7.5, and 10 mg/mL. In all experiments at least one negative control 
was included with no CS-ATM in the media. To increase cellular uptake of fluorine, 10% Human 
Serum Albumin (1mg/mL) (Calbiotech) was added to the CS-ATM media 34. After the 24 hr 
incubation period, the mOPCs were washed and analyzed. After 19F labeling, the cells maintained 
in culture for up to 9 days. The cells were typically analyzed shortly after removal of the CS-
ATM compound to prevent signal dilution from concurrent cell divisions after 19F reagent 
removal.  
hOPC labeling was done by incubating CS-ATM at 4 mg/mL diluted in M1 media for 24 
hrs. After incubation the cells were washed repeatedly with PBS and fixed with Formalin (Fisher 
Scientific, 1:10 dilution). 
 
Fluorescence Labeling Analysis  
 Fluorescence was measured using fluorescence microscopy on the Leica CTR HS 
microscope and Leica Application Suite Advanced Fluorescence 3.1.0 software. Post image 
analysis was completed with ImageJ. 
For in vitro analysis, the cells were fixed on the plate or in suspension using Formalin. 
The cells were then counter stained with Dapi, diluted 1 to 1000 in PBS with .1% Tween (PBS-
T), incubated for 2-5 minutes, and then washed with PBS. Fluorescence microscopy was used to 
visualize the cells. Overlaid images were obtained in the Red, Green, and Blue channels to 
confirm normal cell morphology and CS-ATM uptake by eGFP positive cells, designated by red 
fluorescence. The exposures and intensity for each channel were held constant for each 
experimental trial.  
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The images of red fluorescence were used to determine Relative Fluorescent Units (RFU) 
and quantify CS-ATM uptake. Overlaid images in the red and blue channel were used to 
determine the amount of CS-ATM (red) per cells, designated by Dapi staining. The quantification 
was done using the Color Histogram plugin on image processing software, ImageJ. This plugin 
calculated the total amount of red pixels and total amount blue pixels in a selected area of the 
image. The red pixel value was divided by the blue pixel value to determine the amount of red per 
cell for each image. For each sample, 5 random fields were analyzed. The average of the 5 fields 
was used for the final analysis.  
The CS-ATM nanoemulsion contains red fluorescent dyes directly conjugated to the 19F. 
Because of this, the relative amounts of fluorine per cell can be estimated by the fluorescence 
values in order to derive a relationship between the cellular 19F labeling for different 
concentrations of CS-ATM.   
 
Nuclear Magnetic Resonance Spectroscopy for Quantification of 19F 
 For an accurate quantification of fluorine content per cell, high-resolution nuclear 
magnetic resonance (NMR) spectroscopy was used. Samples were prepared by labelling HLF 
cells and mOPCs as described with CS-ATM. After 24 hrs of labelling, the cells were washed 
with PBS, harvested using accutase, and counted. According to the cell counts, appropriate 
aliquots were removed to obtain a sample of 100,000 cells. Each sample was spun down to obtain 
a dry cell pellet. The cell pellets were resuspended in a NMR lysis buffer, according to the 
manufacturer’s instructions. The NMR lysis buffer contains 25% deuterium oxide (D2O) at >95% 
purity (Sigma-Aldrich), 25% 2% Trion X-100 (Sigma-Aldrich), and 50% .01% Trifluoroacetic 
acid (TFA). The presence of D2O allows for the hydrogen on the –OH group on the acid to be 
replaced with deuterium, which prevents hydrogen bounding between molecules to give a clear 
NMR spectrum. Triton X-100 was used to lyse the cells by permeablizing the membrane, 
  17 
allowing the intracellular components (19F) to be analyzed. TFA provided and internal reference 
used to calibrate the fluorine NMR spectrum.  
 Prepared samples of known cell concentrations were delivered to the University of 
Minnesota NMR center. A 600 MHz spectrometer with the AutoX Dual BB PFG probe was used 
for all fluorine NMR analysis. Both the CS-ATM and TFA reference appear as a single, narrow 
resonance peak, at -91 and -76 ppm, respectively. After data acquisition, the integrated area under 
each peak was calculated and used to determine the amount of fluorine atoms per cell for each 
sample. The amount of fluorine per cell (F/C) was calculated with the formula provided by 
Celsense: 
 
The calculated values of fluorine molecules per cell were used in correspondence with 
MRI phantom experiments to determine the number of cells necessary to generate a signal with 
enough intensity to be visualized using the MRI technologies.    
 
Magnetic Resonance Imaging of 19F  
 Imaging was performed at the Center for Magnetic Resonance Research (CMRR) at the 
University of Minnesota. The Varian 16.4T MRI scanner was used for all imaging experiments. 
 Initial magnetic resonance imaging (MRI) experiments were done to validate the fluorine 
detection by the custom made dual-tone coil and to determine the amount of 19F molecules 
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needed for visualization. The first cell-free “phantom” experiment consisted of six 0.2 mL PCR 
tubes filled with equal amounts of CS-ATM, 10 µL diluted to 200 µL with PBS, place evenly in a 
2 cm diameter circle in a custom made foam container. This phantom was used to ensure a 
uniform magnetic field throughout the coil. 
 The second cell-free phantom experiment was used to identify the range of fluorine 
needed to produce a clear image. A similar custom made foam apparatus was used, containing six 
PCR tubes with different amounts of CS-ATM, 0.1, 0.5, 1, 5 and 10 µL. This experiment was 
used to determine the lower limit of fluorine needed for signal detection. These amounts were 
used because of the known positive control (10 µL) to generate a signal, and smaller, biologically 
relevant amounts. 
 The third phantom experiment was used to observe 19F signal detection in cells. Four cells 
samples containing 300,000, 600,000, 1 million, and 1.5 million cells were labeled with 5 
mg/mL. This concentration of CS-ATM was used based on NMR fluorine quantification in 
mOPCs and the cell numbers were calculated from the second MRI phantom results. One 
negative control with PBS only and one positive with 0.5 µL CS-ATM in PBS were included and 
all 6 samples were placed in the custom foam apparatus. 
 
Part B: Characterization of Transplanted Oligodendrocyte Progenitor Cells in the Injured Rat 
Spinal Cord 
Cell Characterization after Transplantation into Injured Rat Spinal Cords 
A short term study was conducted to observe and characterize iPS cell derived OPCs 
after transplantation into an injured rat spinal cord. This study was done to validate the use and 
safety of OPCs in the spinal cord, as well as track and characterize OPCs after transplantation, 
without 19F labeling.  
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 Athymic nude rats received 200 kD contusion injuries, followed by OPC transplantation 
9 days post injury (DPI). Each rat received four injections, two rostral and two caudal to the 
injury site on the right and left sides of the cord. A total of 300,000 cells were transplanted into 
each rat, with 2.5 µL of cell suspension per microinjection. Eight rats received mOPC transplants, 
2 rats were injected with media only controls, and 10 rats received hOPC transplants. After 1 day, 
1 week, or 1 month the spinal cord from each rat was harvested and fixed.   
 The tissues were frozen in a freezing media, optimal cutting temperature (OCT) 
embedding media (Fischer Healthcare Tissue Plus®). Each spinal cord was completely embedded 
in OCT in a cryomold. The block was frozen in dry ice and stored at -80°C.  
 All tissues were processed as frozen sections, obtained using the Leica CM 3050S 
cryostat. The CryoJane® tape transfer system (Leica Biosystems) was used for sectioning.  The 
slides were mounted on CSFA (Leica Biosystems) adhesive slides, placed in a slide rack, and 
stored at -80° C.  
 
Immunohistochemistry 
 Frozen tissue sections were analyzed using immunohistochemistry to detect and 
characterize transplanted iPS cell derived OPCs in the injured rat spinal cord. 
 Frozen sections from -80° C were brought to room temperature and warmed to 37°C to 
melt the surrounding OCT and further adhere the tissue sections to the slide. The slides were then 
washed in PBS to rehydrate the tissue. A Dako barrier pen was used to create a hydrophobic 
barrier around each section to keep liquids tightly on each section. The tissue was permeablized 
with PBS + 0.1% Triton X-100 to enable antibody entry into the cells, followed by blocking in 
PBS + 1% Horse Serum (1mg/mL, Jackson ImmunoResearch) to prevent non-specific antigen 
binding. The tissue was then incubated overnight with primary antibodies diluted in an incubation 
buffer, 1% Bovine Serum Albumin (BSA) (Sigma-Aldrich), 1% normal donkey serum (Jackson  
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ImmunoResearch), 0.3% Triton x-100, and 0.01% sodium azide (Fluka Biochemika). BSA and 
donkey serum are included for additional blocking to prevent non-specific binding, Triton X-100 
allows antibody entry into cells, and sodium azide works to preserve antibody binding. For a 
complete list of antibodies used Table 1.  
 On the following day, the sections were washed and incubated with secondary antibody 
diluted in incubation buffer. The slides were washed and then stained with Dapi (1:1000) for 
visualization of the nuclei. Immunofluorescence was analyzed using fluorescent microscopy and 
post image analysis was done using Adobe Photoshop and ImageJ. Positive and negative controls 
were obtained for each antibody used. Positive controls were performed on control CNS tissue 
without cell transplants. Sections receiving only the secondary antibody were used as negative 
controls.  
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Table 1: Primary and Secondary Antibody List 
 
OPC Primary Antibodies  
Antigen Host Dilution Staining Company 
Catalog  
Number 
SC121 Mouse 1:500 Cytoplasmic Stem Cell Proven AB-121-U-050 
MBP Rat 1:250 Structural Abcam ab7349 
Olig 2 Rabbit 1:250 Nuclear Millipore AB9610 
Pax 6 Mouse 1:25 Nuclear DHSB N/A 
Beta III Tubulin Mouse 1:1000 Structural Millipore AB9354 
Ki67 (SP6) Rabbit 1:500 Nuclear Abcam ab1667 
APC Mouse 1:200 Nuclear Calbiochem OP80 
GFAP Mouse 1:500 Structural Milipore MAB360 
NF200 Mouse 1:250 Structural N/A N/A 
 
 
 
 
 
 
 
Table 1: Primary and Secondary Antibody List. Descriptions of each antibody used in this thesis is 
provided.  
 
 
 
 
 
 
 
 
 
Secondary Antibodies 
Host Raised Against 
Emission  
Wavelength Company Catalog Number 
Donkey Mouse 555 Life Technologies A3170 
Donkey Rabbit 555 Life Technologies A31572 
Donkey Rat 555 Alexa Fluor A21434 
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Results 
Part A: Cell Labeling and Tracking with 19Fluorine 
Labeling HLF cells with 19F 
Initial in vitro cell labelling experiments were performed using human lung fibroblasts 
(HLF). Toxicity and cell viability were determined after labelling with increasing amounts of 19F 
Celsense reagent. The concentrations used were 2.5, 5, 7, 10, 12.5, 15, 17, 20, 25, and 30 mg/mL 
of 19F Cell Sense reagent, with two negative controls lacking fluorine (Figure 3 A-F). The cells 
were treated with the 19F Cell Sense reagent diluted in HLF media for 24 hours, followed by 
washing to remove the reagent from the media and additional culture for 2 days before analysis. 
The amount of time for labeling (24 hours) was not used as a variable based on previous findings 
suggesting that 24 hours is optimal for highest 19F concentrations and minimal cell toxicity34. 
 
Confirming 19F uptake and viability of 19F labeled Cells 
Fluorine uptake was confirmed by fluorescent microscopy, utilizing the red fluorescent 
dye conjugated to the reagent (Figure 3A-F). There was a visible increase in red fluorescence, 
however this was not quantified. Viability testing using Trypan blue determined the cell survival 
in increasing 19F reagent concentrations (Figure 3G-H). In conditions without reagent, the cell 
viability ranged from 95%-100% (Figure 3G). In the two highest concentrations, 25 and 30 
mg/mL, the cell death increased to 13% (Figure 3H). During analysis, cells were persistently 
growing, indicating that the Cell Sense reagent does not terminate cell growth. Previous 
publications have indicated that 19F CS-ATM labeling concentrations between 2-5 mg/mL 
provide an optimal balance between cell labeling and cell death 34,40,42. In our study with HLF 
cells this concentration results in 95% cell viability. These viability values indicate that CS-ATM 
can be used in HLF cells with minimal effects on cell death and proliferation. 
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Previous studies have indicated that the presence of Human serum albumin (HSA) in the 
culture medium can increase 19F reagent uptake in human cells in vitro 34. Fluorescence analysis 
revealed increased fluorescence in labeled cells with HSA present in the media compared to cells 
loaded with the same concentration of CS-ATM without HSA (Data not shown). 
Figure 3: CS-ATM Labeled HLF Cells and Viability 
 
 
 
Figure 3: CS-ATM Labeled HLF Cells and Viability. (A-F) HLFs labeled with CS-ATM DM Red 
visualized using fluorescence and phase microscopy; 5 mg/mL (A), 10 mg/mL (B), 15 mg/mL (C), 20 
mg/mL (D), 30 mg/mL (E), and a negative control (F). Scale bars all indicate 100 µm. Cell viability 
was determined by calculating cell death observed by Trypan Blue staining. The percent of cell death is 
shown as a table (G) and graphed (H).  
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Quantification of 19F in HLF Cells Using Nuclear Magnetic Resonance Spectroscopy  
  Nuclear Magnetic Resonance (NMR) spectroscopy was used to accurately quantify the 
fluorine content of 19F labeled cells.  
NMR analysis with HLF cells was performed to establish a protocol for preparing cells 
for 19F NMR detection and to determine the effect of different CS-ATM labeling concentrations 
and HSA on fluorine uptake. HLF cells were incubated with CS-ATM at 3 mg/mL, 3 mg/mL with 
10% HSA, 5 mg/mL, and 5 mg/mL HSA. In addition, two negative controls were used, one with 
HLF media only and the other with 10% HSA in HLF media. On the day of NMR analysis, the 
cells incubated with 5 mg/mL and 10% HSA did not survive from unknown cell toxicity and were 
excluded from the experiment. From the remaining conditions, samples of 100,000 cells were 
brought to the University of Minnesota NMR facility for data acquisition (Figure 4 A-C). The 
results revealed that the samples labeled with 3 mg/mL, 3 mg/mL + 10% HSA, and 5 mg/mL 
contained fluorine in the range of 1011  19F molecules per cell, which is within the typical range 
(1011- 1013  F molecules per cell) according to the manufacturer. The 3 mg/mL + HSA and 5 
mg/mL samples had similar 19F content with 6.24 x 1011 and 6.7 x 1011 19F molecules per cell 
(Table 1, Figure 4D). The 3 mg/mL sample was lower in fluorine content with 1.84 x 1011 19F 
molecules per cell (Table 1, Figure 4D). Overall, these results indicated that NMR detection can 
be used to provide an accurate calculation of 19F content per cell and that the labeling performed 
provides fluorine uptake consistent with previous reports and the manufacturer’s findings. 
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Figure 4: 19F Quantification in HLF Cells using NMR 
 
 
 
Figure 4: 19F Quantification in HLF cells using NMR. Cell samples labeled with CS-ATM at different 
concentrations were analyzed with NMR spectroscopy. (A-C) Example spectrums obtained from NMR 
are provided for the negative control (A), 3 mg/mL with 10% HSA (B), and 5 mg/mL (C) labeling 
concentrations. On the spectrums, Ir designates the TFA reference peak at -91 ppm and Is designates 
the Cell Sense reagent peak at -76 ppm. The spectrums were used to calculate the amount of fluorine 
molecules per cell, shown in D.  The X axis represents the labeling concentration, where the 3’ 
indicates 3 mg/mL with 10% HSA and the Y axis is the amount of fluorine per cell. The numbers 
indicated on the graph are x1011. 
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Labeling mouse iPSC-derived OPCs with 19F 
miPS cell derived OPCs were labeled with the 19F CS-ATM reagent to determine 
conditions for optimal cell labeling with minimal cell death. mOPCs were incubated overnight 
with 2.5, 5, 7, and 10 mg/mL 19F Cell Sense reagent diluted in mOPC media, followed by a 24 
hour wash period. Fluorine uptake was confirmed using fluorescent microscopy (Figure 5A-D).  
Quantification of 19F labeling in OPCs using Relative Fluorescence 
 The 19F labeling in OPCs can be estimated by directly observing the fluorescence of the 
BODIPy-TR conjugated to CS-ATM. This compares the efficiency of labeling or the amount of 
fluorine present between different experimental groups.  
Images of labeled and unlabeled mOPCs were obtained by fluorescent microscopy using 
the same imaging parameters for each condition. The total fluorescence detected in the red 
channel (Figure 5 A-D) was converted to Relative Fluorescent Units (RFU) using image analysis 
software and is presented as the amount of fluorescence per cell for each labeling concentration 
(Figure 5E). The RFU increased with increasing CS-ATM concentrations with a linear trend. CS-
ATM labeled cells were maintained in culture for up to 9 days and red fluorescence was still 
detectable after this time, although the total fluorescence appeared to decreased from the 2 day 
analysis time point by visualization. 
 
Cell viability of 19F labeled miPSC derived OPCs 
Aliquots of 19F labeled OPCs from each labeling condition were assessed for viability 
after fluorine uptake using Trypan Blue. Cell survival of at least 95% was determined for each 
condition (Figure 5F), consistent with our previous results using HLF cells.  
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Figure 5: CS-ATM Labeled mOPCs and Relative Fluorescence 
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NMR analysis of 19F labeling in miPSC-derived OPCs 
 NMR analysis was completed to accurately quantify the amount of fluorine uptake in 
mOPCs.  
Two samples of mOPCs incubated with 5 mg/mL, 7.5 mg/mL, and 10 mg/mL each 
underwent NMR spectroscopy (Figure 6E-H). The higher incubation concentrations of CS-ATM 
were used in an attempt to maximize the cellular fluorine content and identify the most effective 
labeling concentration. The amount of 19F per cell was determined for each sample and revealed 
similar concentrations of fluorine per cell in the range of 6-7 x 1011 19F molecules per cell (Table 
1, Figure 6F). These concentrations are similar to but slightly lower than the HLF results for 5 
mg/mL (Table 1). 
Based on the NMR results, the optimal 19F labeling concentration for mOPCs was 
determined to be 5 mg/mL and was used as the incubation concentration for the remainder of 
experiments. Almost the maximum fluorine uptake detected was achieved with 5 mg/mL, with 
only slight increases in 19F molecules per cell detected with higher incubation concentrations.  
 This quantification of 19F per cell is necessary to calculate the amount of labeled cells 
required to visualize the fluorine signal with Magnetic Resonance Imaging (MRI). 
 
 
 
 
 
Figure 5: CS-ATM Labeled mOPCs and Relative Fluorescence. (A-D) mOPCs labeled with CS-
ATM DM Red at different labeling concentrations visualized using fluorescence microscopy 
overlaid with phase images, with 2.5 mg/mL (A), 5 mg/mL (B), 7.5 mg/mL (C), and 10 mg/mL (D) 
of Cell Sense reagent. Scale bars are all 100 µm. Quantification of fluorescence as Relative 
Fluorescent Units (RFU) is shown in E. The X axis represents the labeling concentration of CS-
ATM and the Y axis is the average RFU per sample. The percent of cell survival after labeling is 
also shown for each labeling concentration (F).   
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Figure 6: 19F Quantification in mOPCs using NMR spectroscopy. (A-D) Fluorescent images were 
taken prior to harvesting for NMR to confirm fluorine uptake (red) in mOPCs expression 
transmembrane EGFP. Different labeling concentrations, 0 mg/mL (negative control) (A), 5 
mg/mL (B), 7.5 mg/mL (C), and 10 mg/mL (D), of Cell Sense reagent are shown. Scale bars are 
100 µm Corresponding NMR spectrums (E-H) for 0 mg/mL (E), 5 mg/mL (F), 7.5 mg/mL (G), 
and 10 mg/mL (H) labeling concentrations. On the spectrums, Ir designates the TFA reference 
peak at -91 ppm and Is designates the Cell Sense reagent peak at -76 ppm. The spectrums were 
used to calculate the amount of fluorine molecules per cell, shown in I.  The X axis represents the 
labeling concentration, where the 3’ indicates 3 mg/mL with 10% HSA and the Y axis is the 
amount of fluorine per cell. The numbers indicated on the graph are x1011. 
 
Figure 6: 19F Quantification of mOPCs using NMR Spectroscopy 
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Table 2: Summary of NMR Spectroscopy Results 
 
Labeling human iPSC-derived OPCs using 19F  
hiPSC derived OPCs were also labeled using CS-ATM. hOPCs were incubated with 4 
mg/mL CS-ATM diluted in hOPC media for 24 hours. HAS was not used in the 19F culture, but is 
an area of future interest. After incubation and washing, the cells were fixed and fluorine uptake 
was confirmed with fluorescence microscopy (Figure 7B-D). No difference in cell morphology 
Table 2: Summary of NMR spectroscopy Results. The NMR results for both the HLFs and mOPCs 
are listed here. In the first round of NMR, HLFs labeled with CS-ATM at 0 mg/mL, 3 mg/mL, 3 
mg/mL + 10% HSA (designated as 3’), and 5 mg/mL. Each sample contained 100,000 cells. mOPCs 
were labeled with 0, 5, 7.5, and 10 mg/mL CS-ATM. All samples contained 80,000 cells, except for 
the 7.5 mg/mL samples with 100,000 cells. Ir represents the integrated area under the TFA reference 
peak and Is represents the integrated area of the major peak of the cell pellet for each sample. This 
information was used in the formula to calculate the number of fluorine atoms per cell (see methods), 
which is recorded in the column 19F/cell. The values in this column are x1011. 
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was identified by microscopy between labeled cells and unlabeled control hOPCs. Further 
investigation is required to identify the optimal labeling concentration and cell viability after 
labeling for this cell population, including RFU analysis and NMR spectroscopy.  
Figure 7: CS-ATM Labeled Human iPS cell derived OPCs. 
 
 
 
 
 
Figure 7: CS-ATM Labeled Human iPS cell derived OPCs. (A-D) hOPCs labeled with 4 mg/mL CS-
ATM. Fluorescent images overlaid with phase to confirm uptake of fluorine. A-C are the same field 
taken at 20x of phase (A), red (B), and overlay (C). D shows a closer view of the overlaid image 
indicated by the black box on (C). 100 µm scale bar. 
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Magnetic Resonance Imaging of 19Fluorine 
The purpose of labeling cells with 19F is to visualize fluorine labeled cells using MRI 
technology. To accomplish this, a custom made, dual-tone coil was generated by the University 
of Minnesota Center for Magnetic Resonance Research (CMRR) to detect 19F signals. This can be 
used in combination with the proton signals generated from the Varian 16.4 T MRI scanner to 
create an overlaid image allowing visualization of the fluorine signal in cell or tissue context. The 
fluorine image would reveal cell “hotspots” on the proton image, allowing visualization of where 
the cells are located within the imaged tissue. This method would enable the CS-ATM compound 
to be used for tracking labeled cells after transplantation. 
 
19F detection by MRI in cell-free experiments 
Two cell-free “phantom” experiments were used to examine the feasibility of imaging 
this fluorine reagent in vivo and to determine the optimal imaging configuration and settings.  
The first phantom experiment used a relatively high concentration of CS-ATM (6 
mg/mL, 1.55x1019 fluorine molecules) per sample arranged in our holding device (Figure 8A) to 
measure the homogeneity of the magnetic field inside the coil and magnet. Each of the 6 samples 
were visualized with minimal differences in pixel intensity, indicating a constant magnetic field 
within the imaging platform (data not shown). A consistent magnetic field is important to obtain 
accurate images; inconsistencies in the magnetic field can result in differences in detected 
fluorine signal intensities that are not indicative of differences in fluorine concentration.  
A second cell-free “phantom” of CS-ATM was used to determine the minimum amount 
of 19F molecules needed to produce a detectable signal with a high signal to noise ratio with MRI. 
The amount of fluorine molecules per tube were calculated and used based on physiological 
relevance. Six tubes were imaged, 5 tubes containing 1.55x1019, 7.75x1018, 1.55x1018, 7.75x1017, 
and 1.55x1017 fluorine molecules and 1 tube without 19F (Figure 8C). Of the 5 tubes containing 
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CS-ATM, 4 could be seen (Figure 8B). The signal from tubes designated 2 and 3 was weakly 
detected, however the 19F amounts in these samples were able to produce a signal strong enough 
to differentiate the signal from the background noise. The image was adjusted to optimize 
visualization of tube 4. The results of this image indicated the lower limit for 19F detection to be 
between 1.55 x 1017 and 7.75 x 1018 19F molecules per 0.2 mL tube.          
Figure 8: Cell-Free Phantom MRI Experiments 
   
 
 
 
 
Figure 8: Cell-Free Phantom MRI Experiments. (A) A custom made apparatus was designed to 
hold 6 samples within a 2 cm diameter. The image obtained for the dose response of CS-ATM 
reagent alone is shown in B. Circles are drawn around the location of all 6 images, with 1 in the 
counter clock wise position next to 2, and 0 in between 1 and 6. (D) A table containing the 
fluorine concentrations is provided.  
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MRI detection of 19F labeled cells 
The third phantom experiment was designed to validate 19F signal detection in CS-ATM 
cells and determine the required number of cells to generate a detectable image. The results from 
this phantom can be used to calculate the number of cells required per voxel to produce a 
detectable 19F signal. The number of cells used in this experiment were based on the results from 
the second MRI phantom and the average concentration of 19F per cell labeled with 5 mg/mL CS-
ATM reagent detected by NMR analysis (6.3 x 1011 19F molecules per cell) (Table 2).  
From our calculations, it was predicted the sample containing the highest number of cells 
would produce a signal with an intensity similar to the control sample containing the same 
amount of fluorine without cells, with each subsequent sample providing signals decreasing in 
intensity. However, following MRI analysis, the amount of fluorine in each tube and the positive 
control were insufficient to generate a visible signal against the background noise. 
The MRI results confirm that under our conditions, the CS-ATM reagent can be 
visualized using MR technologies, however the labeling efficiency with mOPCs will require a 
higher cell concentration for appropriate signal intensity to create an optimal image. A 
combination of improvements could be utilized to generate a strong 19F signal in vivo, including 
increased transplanted cell numbers, longer scan times, and optimization of the dual-tone coil to 
increase sensitivity. The 0.2 mL PCR sample tubes in the phantom experiments were used 
because of appropriate size and non-reactivity with the dual-tone coil, and to provide a sample of 
similar area size to that of a rat spinal cord analyzed after cell transplantation.  
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Table 3: Cell Number and Fluorine Concentration for Cell Phantom MRI Experiment. 
 
 
Part B: Characterization of Transplanted Oligodendrocyte Progenitor Cells in the Injured Rat 
Spinal Cord 
 Short term experiments were conducted transplanting iPSC derived OPCs into rat spinal 
cords following contusion injury as described in the methods section; 20 age-matched rats were 
injured and received cell transplants 9 days later. Two of the rats were used as control animals, 8 
rats received mOPCs, and 10 rats received hOPCs. One of the rats receiving hOPCs died shortly 
after the injection procedure, and the rest were sacrificed according to the timeline described 
(Figure 9). The purpose of this short term experiment is to determine if the transplanted iPS cell 
derived OPCs survive in the rat spinal cord after injection and to further characterize the 
transplanted cells after in vivo differentiation. This aspect of our study does not focus on 
functional improvement after cell transplantation in this model of spinal cord injury.  
 
 
 
Table 3: Cell Number and Fluorine Concentration for Cell Phantom MRI Experiment. For each 
sample number, the corresponding cell number and fluorine content per tube are listed. Samples 0 
and 5 represent the negative and positive controls, with no cells or fluorine and CS-ATM 19F only, 
respectively.  
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Figure 9: Short Term Rat Experimental Timeline 
 
 
Histological Analysis of Spinal Cords Receiving mIPSC derived OPCS  
 The mOPCs used in this study express transmembrane bound eGFP. This allows for 
identification of transplanted cells by fluorescence microscopy. The majority of sections from 
injured rat spinal cords receiving miPS cell derived OPC transplants were found to contain eGFP 
expressing cells (Figure 10). 
 
 
 
 
 
 
 
 
 
 
Figure 9: Short Term Rat Experimental Timeline. The rats receive contusion injuries 9 days before 
iPSC derived OPC transplants. Spinal cord tissues are harvested at 1 day, 1 week, and 1 month (28 
days). 
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Figure 10: miPSC derived OPCs in the Injured Rat Spinal Cord 
 
 
Characterization of Transplanted mOPCs with Immunohistochemistry 
By one week after injection, the mOPCs have integrated into the tissue and have 
processes that are distant from the cell body and nucleus (Figure 10 B-D). This is a typical 
characteristic of OPCs becoming oligodendrocytes, creating projections that span and align with 
Figure 10: miPSC derived OPCs in the injured Rat Spinal Cord 1 week after transplantation. (A) A 
single parasagittal section containing eGFP expressing mOPCs merged with Dapi (blue). The dorsal 
and ventral sides of the spinal cord are the top and bottom, respectively. Scale bar 600 µm. A closer 
view of eGFP cells merged with Dapi in the rat spinal cord at 10x (B) and 20x (C). Scale bars 100 µm. 
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neuronal axons to produce the protective myelin sheath. The projections seen confirm that the 
transplanted cells adopt the appropriate morphology of the oligodendrocyte lineage.  
 Further characterization of the transplanted mOPCs is ongoing, primarily through IHC. 
The antibodies that are being investigated include markers of OPCs and the oligodendrocyte 
lineage, Olig2, APC, MPB; cell division, Ki67; neurons, NF200, βIII Tubulin; and astrocytes, 
GFAP (Table 3). Olig2 (Oligodendrocyte lineage transcription factor 2) and APC (Adenomatous 
Polyposis Coli) are transcription factors expressed in the nucleus of cells in the oligodendrocyte 
lineage. Expression of these transcription factors in eGFP expressing cells confirms that the 
transplanted cells remained in the oligodendrocyte lineage and did not adopt another cell fate45. 
Myelin Basic Protein (MBP) is the major component of the myelin sheath, and can be seen in 
myelinating oligodendrocytes. The neuronal markers neurofilament (NF200) and βIII Tubulin 
have two functions; one to confirm that the transplanted mOPCs do not become neurons after 
injection, and two to visualize the interaction between the eGFP projections with the neuronal 
tracts. Finally, glial fibrillary acidic protein (GFAP) is used to show that the majority of 
transplanted cells do not adapt an astroglial fate.  
 
Immunohistochemistry of Oligodendrocyte Markers 
The majority of the markers have been analyzed in relation to the transplanted mOPCs, 
however the entirety of the cords have not been processed and quantification has not been 
completed. In most areas of dense eGFP expression, there is increased Olig2 expression 
compared to what is found in the endogenous spinal cord (Figure 11). Further analysis with 
confocal microscopy is required to definitively identify the nuclei corresponding to the eGFP 
transplanted cells. Additionally, APC expression was found near areas of eGFP expression 
(Figure 12A-B). APC indicates later-stage OPCs as they are differentiating into oligodendrocytes, 
thus a large percentage of APC expression mOPCs is not expected after 1 week in the spinal cord.  
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 In culture, mOPCs are relatively proliferative when maintained in mOPC media. 
However, it is expected that after transplantation, the cells will be subjected to an environment 
promoting differentiation compared to proliferation. Ki67 staining has supported this hypothesis 
with a small fraction of the transplanted cells positive for Ki67, while the majority of mOPCs are 
negative. Figure 12C and D illustrate one area of Ki67 positive nuclei near a patch of eGFP 
expressing cells.  
Figure 11: Olig2 analysis of mOPCs in the Injured Rat Spinal Cord 
 
 
 
 
 
Figure 11: Olig2 Analysis of mOPCs in the Injured Rat Spinal Cord 1 week after 
transplantation. Fluorescent microscopy images of eGFP expressing cells with Olig 2 
expression (Red) at 20x (A-C), and 40x (D-F). 
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Figure 12: APC and Ki67 Analysis of mOPCs in the Injured Rat Spinal Cord 
 
 
 
 
 
Immunohistochemistry of Neuronal and Astroglial Markers 
 The neuronal markers NF200 and βIII Tubulin rarely overlap with the eGFP expressing 
mOPCs, confirming that the transplanted cells are not generating neurons. These markers show a 
Figure 12: APC and Ki67 Analysis of mOPCs in the Injured Rat Spinal Cord 1 week after 
transplantation. Fluorescent microscopy images of eGFP expressing mOPCs with APC 
(Red) at 20x (A) and 40x (B) objectives. Example images of positive Ki67 (Red) at 20x 
(C) and 40x (D) objects are shown. Scale bars are 100 µm (A,C) and 50 µm (B,D). 
  41 
relationship between the eGFP mOPCs and neuronal tracts, as the eGFP projections appear to 
associate the neuronal tracts (Figure 13). Confocal microscopy will be utilized to further describe 
this relationship. Finally, a minimal amount, approximately less than 10% of the transplanted 
cells have become astrocytes, as indicated by GFAP staining (Figure 14).  
 Additionally, there is no evidence of tumor growth at the 1 day or 1 week time points. 
This is an important finding, providing evidence for the safety of transplanted mOPCs in an 
injured rat spinal cord.   
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Figure 13: Neurofilament and βIII Tubulin Analysis of mOPCs in the Injured Rat Spinal 
Cord 
 
 
 
 
 
 
 
 
Figure 13: Neurofilament and βIII Tubulin Analysis of mOPCs in the Injured Rat 
Spinal Cord 1 week after transplantation. Fluorescent microscopy images of eGFP 
expressing mOPCs with neurofilament (NF200) (Red) at 20x (A) and 40x (B) 
objectives, and βIIITubulin (Red) at 20x (C) and 40x (D). Scale bars are 100 µm 
(A,C) and 50 µm (B.D).   
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Figure 14: GFAP Analysis of mOPCs in the Injured Rat Spinal Cord 
 
 
 
 
 
 
Figure 14: GFAP Analysis of mOPCs in the Injured Rat Spinal Cord 1 week after 
transplantation. Fluorescent microscopy images of eGFP expressing mOPCs with 
GFAP staining (Red) at 10x (A) and 20x (B and C). A zoomed in square of C is 
displayed in D, as indicated. Scale bars are 100 µm.  
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Characterization of transplanted hiPSC derived OPCs  
 The transplanted hOPCs in the short term rat experiment do not express a lineage tracer, 
such as eGFP, making tracking of the transplanted cells more challenging. The host and donor 
cells are from distinct species allowing for multiple techniques to distinguish the cells from each 
species.  In this experiment, antibodies against human cells, SC121, a human cytoplasmic marker, 
is used to distinguish transplanted human cells from endogenous rat cells. The cytoplasmic 
marker, SC121, works well with minimal non-specific binding, labeling the majority of each 
human cell to show the morphology and projections (Figure 15, Figure 16).  
 Utilizing the SC121 antibody, the transplanted human cells can be seen after 1 day, 1 
week (Figure 15), and 1 month (28 days) (Figure 16), providing evidence that transplanted human 
cells can survive in the rat spinal cord without the use of additional immunosuppression. This 
antibody has also shown that many of the human cells on the perimeter of the transplanted cells 
have obtain a morphology similar to oligodendrocytes, with long, thin processes (Figure 16). 
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Figure 15: hiPSC derived OPCs in the Injured Rat Spinal Cord 1 week after 
Transplantation 
 
 
 
 
 
 
 
 
 
 
Figure 15: hiPSC derived OPCs 1 week after transplant to injured rat spinal cord. (A) A tiled 
image of a single, parasagittal rat spinal cord section containing SC121 positive human cells 
(green). Close up images at 10x (B) and 20x (C) objectives displaying human cells in the rat 
spinal cord with Dapi (blue). Scale bars are 250 µm (A) and 100 µm (B,C) 
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Figure 16: hiPSC derived OPCs in the Injured Rat Spinal Cord 1 Month after 
Transplantation 
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Characterization of the transplanted hiPSC derived OPCs is ongoing, however some of 
the initial staining has been completed. There appears to be overlap of SC121 with Olig2 
expression, however further analysis with confocal and human nuclear antigen is required (Figure 
17). Additionally, Ki67 staining shows that a small population of the transplanted hOPCs are 
dividing. Pax 6 expression was also analyzed to determine if the transplanted cells are generating 
neurons. A small subset of transplanted hOPCs are near patches of Pax 6 expression. However, 
the majority of hOPCs appear to remain in the oligodendrocyte lineage. Further analysis of these 
transplanted cells is required for complete characterization. Overall these results demonstrate that 
the hiPSC derived OPCs can survive after transplantation into the injured rat spinal cord. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: hiPSC derived OPCs in the Injured Rat Spinal Cord 1 month after 
transplantation. (A) A tiled image of a single, parasagittal rat spinal cord section 
containing SC121 positive human cells (green). Close up images at 20x (B and C), 10x 
(D), and 40x (E) objections displaying human cells in the rat spinal cord counterstained 
with Dapi (blue). Scale bars are 100 µm. 
  48 
Figure 17: hiPSC derived OPCs Counterstained with Olig2 in the Injured Rat Spinal Cord  
 
 
 
 
 
 
Figure 17: hiPSC derived OPCs Counterstained with Olig2 in the Injured Rat Spinal Cord. 
Rat spinal cords receiving hOPC transplants were stained for SC121 to label human cells 
(green) and counterstained with Olig2 (red). Fluorescent images taken at 20x (A and B), 
and 40x (C and D) objectives are shown. Scale bars are as 100 µm (A,B) and 50 µm (C,D). 
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Discussion 
 The purpose of this research was to validate the use of 19fluorine labeling to track 
oligodendrocyte progenitor cells in vivo after transplantation into injured rat spinal cord and to 
characterize transplanted oligodendrocyte progenitor cells in injured rat spinal cords.  
 The results from ex vivo cell labeling with the 19F Cell Sense reagent are consistent with 
published data, confirming low toxicity and minimal phenotypic effects after labeling. The use of 
HSA in the culture medium increased fluorine uptake by cells, supported by NMR analysis, 
similar to results found by Bible et al. (2012). In the HLF cell NMR analysis, the sample 
containing 3 mg/mL had fewer fluorine molecules per cell than the sample containing 3mg/mL 
with HSA. Some of this difference can be accounted for by the use of HSA to increase fluorine 
uptake ex vivo, however it is possible that mechanical error is also influencing this large 
difference in fluorine concentration. For instance, the 3 mg/mL sample may have had fewer cells 
than calculated or differences could have occurred in NMR processing. Overall, these ex vivo cell 
labeling findings are consistent with the literature and the manufacturer’s findings, supported by 
accurate NMR quantification of fluorine content per cell. Further analysis of 19F CS-ATM 
labeling in hiPSC derived OPCs is required to accurately quantify fluorine content after labeling 
and to identify the optimal labeling concentration with the greatest fluorine concentration per cell 
to cell death ratio. Replication of the results is necessary for further analysis. 
 Magnetic resonance imaging results validated that a 19F signal can be detected with our 
coil, MRI scanner and instruments, however the amount of cells necessary to generate a signal at 
our labeling efficiency is greater than expected. It is possible to increase the cellular 
concentration within the 0.2 mL PCR tube to generate a signal with an intensity great enough to 
be visualized with our custom made 19F coil. However, in the injured rat spinal cord, increasing 
the cell concentration above 1,500,000 transplanted cells would be impossible due to the 
physiological stress of transplanting such a large quantity of cell into soft tissue. This quantity of 
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cells is realistic for transplantation into injured human spinal cords, however the translation of 
resolution between imaging rats and humans is unclear. The next step will be to quantify the pixel 
intensity of the MR image and to calculate the number of cells required per voxel for 19F signal 
detection. 
 Although visualization of mOPCs labeled with CS-ATM in an injured rat spinal cord is 
challenging, human iPSC derived OPCs may have a higher fluorine uptake efficiency, decreasing 
the amount of cells required to generate a 19F image with MR technologies. Alternatively, it may 
be possible to transplant the appropriate number of labeled mOPCs required for imaging in a 
shiverer mouse brain. Shiverer mice have a genetic defect creating a large deletion in the myelin 
basic protein (MBP) gene, causing extensive dysmyelination in the CNS46,47. This model 
organism is utilized in our laboratory to test myelination by iPS cell derived OPCs. A larger 
quantity and volume of cells can be injected into these mice without causing fatal brain damage. 
With this model, the 19F CS-ATM labeled cells can be visualized with MRI, and the 
quantification and migratory ability of OPCs can be assessed by imaging transplanted OPCs at 
different time points following transplantation. This study would also provide information 
regarding 19F label retention and imaging following transplantation. Label retention is difficult to 
assess ex vivo due to the proliferative phenotype of OPCs in culture, with each cell division 
diluting the 19F signal. Label dilution should not be a problem in transplanted cells as it is 
hypothesized that transplanted OPCs are subjected to a microenvironment that promotes 
differentiation rather than proliferation, however this needs to be confirmed. The ability to track 
transplanted cells in injured spinal cords would allow the relationship between improved function 
and retention of transplanted cells to be assessed. For instance, functional testing, in vivo cell 
tracking of labeled OPCs, and myelin imaging via MRI can be assessed for the same animal at 
different time points, providing more informative results of the progress in each animal 
individually. 
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 The traditional method of tracking cells is to harvest tissue at specific time points after 
transplantation and identify the transplanted cells through histological analysis, primarily 
immunohistochemistry (IHC). The use of in vivo cell tracking with reagents such as CS-ATM 
allows researchers to track the transplanted cells in live animals. In early experiments with 
transplanted, CS-ATM labeled OPCs, it will be important to analyze the tissues at each time point 
after in vivo to confirm the MRI results.  
 Significant advantages of 19Fluorine use for cell tracking in transplantation experiments 
exist, including non-toxicity, high resolution, ability to quantify cells, and potential to visualize 
the biodistribution of the transplanted cells. For safety studies it is important to determine if there 
is accumulation of the transplanted cells in other organs, such as the lungs, which can be detected 
with 19F MRI. However, there are some pitfalls to this tracking approach. One obstacle is 
potential signal dilution after cell division. This may not affect imaging if the fluorine content in a 
specific area remains the same, but if the cell division significantly expands the area in which the 
fluorine molecules are present, the signal intensity will decrease. This result could potentially 
affect cell counts based on fluorine signal, however appropriate controls to identify the amount of 
cell division after transplantation would help estimate this occurrence. Additionally, there is 
potential for false positives. If death of transplanted, labeled cells occurs, it is possible that 
macrophages or phagocytes in the surrounding area may obtain the 19F molecules through cell 
debris. This is a potentially significant problem in the spinal cord after injury as there is 
infiltration of macrophages. To account for this in initial experiments, corresponding analysis of 
the transplanted, injured rat spinal cord using IHC for phagocyte markers would indicate the 
amount of overlap between the red, 19F signal and any phagocytic cells.  
Characterization of OPCs transplanted into the injured rat spinal cords with CS-ATM 
labeling is currently underway. Immunohistochemistry results have confirmed that we can detect 
our transplanted OPCs, both mouse and human, in frozen sections of the rat spinal cord. Further 
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analysis, primarily with confocal microscopy is required to confirm co-expression of transplanted 
cells with OPC and oligodendrocyte markers. 
 The next step in characterization is quantification of transplanted OPCs. Due to the 
transmembrane expression of eGFP, the mOPCs are difficult to quantify given the extensive 
eGFP expressing processes. It is difficult to determine which nuclei corresponds to each eGFP 
cell body. The human SC121 cytoplasmic staining also provides this challenge, however 
quantification of human cells may be accomplished with human nuclear antigen staining. The 
human nuclear antigen provides a solution to total transplanted cell quantification and calculation 
of the percent of transplanted cells co-expressing OPC nuclear markers, however the cytoplasmic 
marker (SC121) is more informative for counterstaining for structural proteins, such as GFAP, 
neurofilament, and MBP.  
Of the characterization completed, IHC results indicate that the transplanted OPCs and 
their progeny are retained, with few transplanted cells generating neurons or astrocytes.  
 Overall, the results of this thesis confirm that the 19F Cell Sense reagent is feasible 
because of low toxicity for use in both mouse and human OPCs, with similar labeling efficiencies 
to other studies and cell types. The MRI technologies available are sufficient to visualize a strong 
19F signal, however a more sensitive dual-tone coil may be required to detect the 19F signal in CS-
ATM labeled OPCs.  
Histological analysis of transplanted OPCs into injured rat spinal cords can be accurately 
assessed based on the parameters determined in this research. In the future, labeled OPCs can be 
transplanted into injured spinal cords and tracked in vivo, as well as characterized by IHC. The 
use of the research 19F with the red fluorescent dye would also help to identify transplanted 
hOPCs prior to staining. This would not only allow for tracking via MR imaging but also using 
fluorescence microscopy visualizing the red fluorescent dye in transplanted cells. The in vivo 
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analysis will not only allow us to track the migration of transplanted cells, but also quantify the 
number of surviving cells and link this to functional improvements after transplant. 
 The use of this FDA approved 19F reagent can be potentially translated directly to human 
use. Future clinical trials investigating cell therapies in patients with chronic spinal cord injury 
would greatly benefit from this in vivo 19F cell tracking method to further assess safety and 
efficacy of transplanted OPCs, both through the tracking and quantification analysis that can be 
pursued with CS-ATM.   
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